Credentialing CDK 4/6 inhibitors with radiation to treat high-risk breast cancer
Official title: Project 3: Credentialing CDK 4/6 inhibitors used with radiation as an effective treatment strategy in locally advanced ER+ and TNBC
Funded at University of Michigan at Ann Arbor · NIH-11420513 · Data updated 2026-11-12
A study from the University of Michigan aims to test whether adding CDK4/6 inhibitors to radiation therapy could improve outcomes for women with high-risk ER+ or triple-negative breast cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | August 14, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $255,536 |
| NIH project number | 5P50CA269022-04 |
| Project ID | NIH-11420513 on NIH RePORTER |
Who could benefit from this research
✓Could help
Women with high-risk breast cancer (ER+ or TNBC) who are receiving standard radiation therapy, especially those with nodal involvement or characteristics noted in the proposal.
✕Less likely to help
Patients unlikely to benefit include those with contraindications to CDK4/6 inhibitors or radiation intolerance, or those diagnosed with disease subtypes not addressed by the study.
What this research studies
This project explores combining CDK4/6 inhibitors with radiation to reduce locoregional recurrence in women with high-risk breast cancer. It builds on existing use of CDK4/6 inhibitors for ER+ disease and investigates their role as radiosensitizers in upfront treatment, including patients with multiple lymph node involvement or TNBC. The study is conducted in a patient-relevant setting, leveraging clinical and translational approaches to understand safety and potential effectiveness. If successful, it could inform new treatment strategies that lower recurrence risk and improve survival for a substantial patient population.
Why it matters
Potential benefit: If successful, patients could experience lower recurrence rates and potentially better survival when CDK4/6 inhibitors are used alongside radiation.
How similar studies have gone: Previous work shows CDK4/6 inhibitors are effective in ER+ metastatic disease, with ongoing exploration in upfront settings; this study extends that potential to combine with radiation.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Speers, Corey W. — University of Michigan at Ann Arbor
- Study coordinator: Speers, Corey W.
Related research
Other NIH-funded projects on the same topics.
-
Globally useful predictor for cervical cancer treatment response
This project aims to develop a simple predictive signature to personalize treatment for locally advanced cervical cancer using easy tests and imaging.
-
Spatial control of immunogenic cancer killing for locally advanced lung cancer
A new approach uses radiation-triggered nanoparticles to deliver cancer-killing drugs directly to lung tumors while sparing healthy tissue.
-
Targeted radiosensitization to improve local control in advanced cancers
A Cancer research grant is exploring how combining radiation therapy with a targeted drug approach could better control locally advanced tumors.
-
Total Neoadjuvant Therapy for Borderline or Locally Advanced Pancreatic Cancer
A multi-part treatment approach tests giving all chemotherapy and targeted radiotherapy before surgery to help patients with tough-to-remove pancreatic cancer become eligible for curative surgery.
-
Blood tests to predict who will respond to pre-surgery therapy for locally advanced rectal cancer
A blood-based test is being developed to predict which patients with locally advanced rectal cancer will respond to neoadjuvant chemoradiation before surgery.
-
Predicting who responds to preoperative therapy for rectal cancer using combined photoacoustic and ultrasound imaging
A study is testing a new imaging method to better predict which locally advanced rectal cancer patients will respond to preoperative treatment so some may avoid unnecessary surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.